Is the Celldex Offering a Reason to Be Scared?
Celldex's offering puts acquisition/partnership rumors by the likes of Roche, Amgen, or Alexion on the back burner. It also raises significant questions prior to a major data release. Does it change the outlook for the Celldex's stock?
UPDATE: Piper Jaffray Initiates Coverage on Alexion Pharmaceuticals as 2014 Biotech Sector Outlook R
UPDATE: Piper Jaffray Initiates Coverage on Alexion Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong
BioMarin: Where Biotech and Rodney Dangerfield Cross Paths
The company with arguably one of the most promising pipelines around gets no respect.
With News of an Investigation, Is This Still an Attractive Biotech Stock?
Questcor may be a cheap and fast-growing orphan biotech, but news of a larger investigation is creating fear among some investors -- but should it?